Business
Everest Medicines Announces Publication of Etrasimod's Asian Multicenter Phase III ENLIGHT UC study (ES101002) Results in The Lancet Gastroenterology & Hepatology
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the results of its Asian multicenter Phase III ENLIGHT UC study (ES101002) of etrasimod (VELSIPITY®) for the treatment of moderately to severely active ulcerative colitis (UC), have been published in the prestigious international journal The Lancet Gastroenterology & Hepatol
About this update from Everest Medicines Ltd.
[{"type":"list","items":[{"val":[{"type":"text","content":"The published study results are from the ENLIGHT UC study (ES101002), a multicenter, randomized, double-blind and placebo-controlled Phase III trial of etrasimod conducted across Asia. The study included a 12-week induction phase followed by a 40-week maintenance phase and represents the largest pivotal Phase III study to date in Asian patients with moderately to severely active ulcerative colitis.","length":401,"tagName":"p"}]},{"val":[{"type":"text","content":"The study results showed that, during both the 12-week induction phase and the 40-week maintenance phase, etrasimod demonstrated statistically significant and clinically meaningful improvements across all primary and secondary efficacy endpoints.","length":246,"tagName":"p"}]},{"val":[{"type":"text","content":"Currently, only around 24% of patients achieve mucosal healing with available treatments. Results from the ENLIGHT UC study demonstrated that after 52 weeks of etrasimod treatment, the mucosal healing rate reached 51.9%, with a mucosal normalization rate of 45.5%.","length":269,"tagName":"p"}]},{"val":[{"type":"text","content":"The safety profile of etrasimod was consistent with previous studies, with no new safety signals observed.","length":106,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1022,"olType":false},{"type":"text","content":"SHANGHAI, Oct. 9, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the results of its Asian multicenter Phase III ENLIGHT UC study (ES101002) of etrasimod (VELSIPITY®) for the treatment of moderately to severely active ulcerative colitis (UC), have been published in the prestigious international journal The Lancet Gastroenterology & Hepatology, marking the global recognition of this next-generation selective S1P receptor modulator's efficacy in Asian patients.","length":699,"tagName":"p"},{"type":"text","content":"ENLIGHT is the largest Phase III trial of moderately to severely active ulcerative colitis in Asia completed to date, with 340 eligible subjects randomized to treatment with etrasimod or placebo. Patients with inadequate response or intole...